Connect with us

Business

Inside Biogen’s scramble to sell Aduhelm: Project ‘Javelin’ and pressure to ID as many patients as possible – Endpoints News

In anticipation of Aduhelm’s approval for Alzheimer’s in June, Biogen employees were directed to identify and guarantee treatment…

Published

on

Article feature image
ADVERTISEMENT

As the saga over how to pay for Aduhelm plays out, biopharma companies are now looking closely at how Biogen was able to keep such a special relationship with FDA officials ahead of the drug’s accelerated approval, and whether or not they might be able…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
A Tesla Megapack burst into flames at ‘Victorian Big Battery’ – The Verge
Article feature image
San Francisco tenants get 6-figure buyout to leave luxe unit – Yahoo News
Article feature image
Royal Caribbean shares tumble as 6 Covid cases discovered on board a ship, cruise line expands U.S. testing policy – CNBC